Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 24.
doi: 10.1002/ana.78049. Online ahead of print.

Dual Antiplatelet Therapy After Ischemic Stroke Stratified by Intracranial or Extracranial Atherosclerotic Stenosis

Yingying Yang #  1 , Jianbo Yang #  2 , Ying Gao  3 , Weiqi Chen  1 , Xuan Wang  4 , Hongyi Yan  4 , Tingting Wang  1 , Yongjun Wang  1   3   4 , Yuesong Pan  1   4 , Yilong Wang  1   3   4   5   6   7   8
Affiliations

Dual Antiplatelet Therapy After Ischemic Stroke Stratified by Intracranial or Extracranial Atherosclerotic Stenosis

Yingying Yang et al. Ann Neurol. .

Abstract

Objective: This objective of this study was to assess the efficacy and safety of clopidogrel plus aspirin for acute mild stroke or high-risk transient ischemic attack (TIA) stratified by the status of symptomatic intracranial atherosclerotic stenosis (ICAS) or extracranial atherosclerotic stenosis (ECAS).

Methods: The study was a subgroup analysis of a randomized clinical trial. Participants with mild ischemic stroke or TIA were assigned to receive either clopidogrel plus aspirin or aspirin monotherapy. Participants were categorized into 4 groups by the status of symptomatic ICAS or ECAS: ICAS + ECAS group, only ECAS group, only ICAS group, and no stenosis group. The primary efficacy end point was any new stroke and the primary safety end point was moderate-to-severe bleeding within 90 days.

Results: The study enrolled 5,664 patients. Compared with other groups, the ICAS + ECAS group had a higher risk of recurrent stroke within 90 days (no stenosis = 5.7%; only ICAS = 7.2%; only ECAS = 10.3%; and ICAS + ECAS = 13.2%; p < 0.001). Although clopidogrel plus aspirin showed a numerically lower recurrence risk versus aspirin alone, no significant treatment effect difference emerged across the 4 groups. No significant interaction between antiplatelet therapy and the status of symptomatic ICAS or ECAS for recurrent stroke and moderate-to-severe bleeding was identified.

Interpretation: For acute mild ischemic stroke or TIA, although patients with both symptomatic ICAS and ECAS exhibited an elevated risk of recurrent stroke than other patients, no interaction effect between antiplatelet therapy and the status of symptomatic ICAS or ECAS for the risk of new stroke and moderate-to-severe bleeding was observed. ANN NEUROL 2025.

PubMed Disclaimer

References

    1. Song JY, Kwon SU. Intracranial atherosclerotic stenosis. Cerebrovasc Dis Extra 2025;15:62–67. https://doi.org/10.1159/000543356.
    1. Wang Y, Meng R, Liu G, et al. Intracranial atherosclerotic disease. Neurobiol Dis 2019;124:118–132. https://doi.org/10.1016/j.nbd.2018.11.008.
    1. White H, Boden‐Albala B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the northern Manhattan study. Circulation 2005;111:1327–1331. https://doi.org/10.1161/01.Cir.0000157736.19739.D0.
    1. Kim JS, Nah HW, Park SM, et al. Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease. Stroke 2012;43:3313–3318. https://doi.org/10.1161/STROKEAHA.112.658500.
    1. Ding X, Li C, Yu K, et al. Different risk factors between intracranial and extracranial atherosclerotic stenosis in Asian population: a systematic review and meta‐analysis. Int J Neurosci 2014;124:834–840. https://doi.org/10.3109/00207454.2013.879580.